Free shipping on all orders over $ 500

Nedaplatin

Cat. No. M3955
Nedaplatin Structure
Synonym:

NDP

Size Price Availability Quantity
10mg USD 90  USD90 In stock
50mg USD 330  USD330 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control
  • Current batch:
  • Purity >98%
  • COA
  • MSDS
Biological Activity

Nedaplatin is a platinum complex that has potent antineoplastic activity. Nedaplatin produces less nausea, vomiting and nephrotoxicity than other platinum-containing products.NDP was developed as a second generation platinum complex.Because it has greater antitumour activity and lower nephrotoxicity than cisplatin (CDDP).Nedaplatin (NDP) is a second-generation platinum complex with reduced nephrotoxicity that may substitute for CDDP or even surpass it for use in combination with other drugs.

Protocol
Cell Experiment
Cell lines Human SCLC cell line SBC-3 and human NSCLC cell line PC-14
Preparation method The inhibition of cell (including human SCLC cell line SBC-3 and human NSCLC cell line PC-14) proliferation after drug treatments as the antitumor activity using a regrowth assay is messured. Briefly, exposing cells to drugs alone or in combination for 6 days at 37°C in an atmosphere of 100% humidity with 5% CO2; then pipetting the cells six to eight times until almost all cells appeared as single cells and counted with a counter. For each drug, concentration-effect curves are drawn as plots of the fraction of surviving cells (unaffected cell fraction, fu) versus drug concentration. The cell proliferation ratio of the treated:control cultures (T:C%) is calculated as follows: [(the number of treated cells on day 6)/(the number of treated cells on day 0)]/[(the number of control cells on day 6)/(the number of control cells on day 0)] × 100%. Defining the IC50 as the drug concentration required for a 50% reduction in the number of cells.Carrying four or five independent experiments out for each. Treating the cells either by simultaneous exposure to the two drugs or by sequential exposure to Nedaplatin followed by irinotecan (Nedaplatin→irinotecan) and vice versa (irinotecan→Nedaplatin) for 3 hours to check the effect of the drug treatment schedule on the effect of the combination . For the sequential exposure treatment, exposing cells to the first drug for 3 hours, ished in fresh medium once, and then immediately exposing to the second drug for 3 hours. Culturing the treated cells in drug-free medium until evaluation
Concentrations 0.005 μg/mL, 0.01 μg/mL, 0.025 μg/mL, 0.05 μg/mL, 0.1 μg/mL, 0.25 μg/mL, and 0.5 μg/mL
Incubation time 6 days
Animal Experiment
Animal models Tumor-bearing athymic BALB/c nude mice with Ma44 or NCI-H460 cells
Formulation Saline
Dosages 10 mg/kg or 20 mg/kg
Administration Administered via i.v.
Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

Chemical Information
Molecular Weight 303.17
Formula C2H8N2O3Pt
CAS Number 95734-82-0
Purity >98%
Solubility DMSO
water 10mg/mL
Storage at -20°C
References

[1] Kanzawa F, et al. Clin Cancer Res. In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction.

[2] Uchida N, et al. Eur J Cancer. Sequence-dependent antitumour efficacy of combination chemotherapy of nedaplatin, a novel platinum complex, with 5-fluorouracil in an in vivo murine tumour model.

[3] Uchida N, et al. Anticancer Res. Antitumor efficacy of nedaplatin, a novel platinum complex, with cyclophosphamide in murine and human tumor model.

Related Products
Cinobufotalin

Cinobufotalin is a cardiotonic steroid, or butadienolide, derived from the skin secretions of toads. SREBP1 is a novel inhibitor that inhibits the proliferation of hepatocellular carcinoma by targeting adipogenesis.

A 438079

A 438079 is A potent, selective P2X7 receptor antagonist with A pIC50 of 6.9.

A 438079 hydrochloride

A 438079 Hydrochloride is A potent, selective P2X7 receptor antagonist with A pIC50 of 6.9.

Abatacept

Abatacept is a CTLA-4 agonist that binds to antigen presenting cells CD80 and CD86, blocks costimulatory signals and inhibits T cell activation, and is used in the study of rheumatoid arthritis and juvenile rheumatoid arthritis.

(-)-Taxifolin

(-)-Taxifolin is a low activity isomer of Taxifolin. Taxifolin has important anti-tyrosinase activity. Taxifolin effectively inhibited collagenase with IC50 of 193.3 μM. Taxifolin is an important natural compound with anti-fibrosis effects. Taxifolin is a free radical scavenger with antioxidant capacity.

  Catalog
Abmole Inhibitor Catalog 2017




Keywords: Nedaplatin, NDP supplier, inhibitors

Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.